Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
7.44
-0.28 (-3.63%)
At close: Apr 28, 2026, 4:00 PM EDT
7.49
+0.05 (0.67%)
Pre-market: Apr 29, 2026, 4:55 AM EDT
Fulcrum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
495.75M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| Valneva SE | 205.07M |
| 4D Molecular Therapeutics | 85.21M |
| ADC Therapeutics | 81.36M |
| XOMA Royalty | 52.15M |
| Verastem | 30.91M |
| Adlai Nortye | 5.00M |
| Upstream Bio | 2.85M |
FULC News
- 1 day ago - Fulcrum Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 1 day ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 - GlobeNewsWire
- 1 day ago - Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors - GlobeNewsWire
- 8 days ago - Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET - GlobeNewsWire
- 5 weeks ago - MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - GlobeNewsWire
- 7 weeks ago - Fulcrum Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - GlobeNewsWire